Sarconeos for treating severe COVID-19 in people aged 45 years and over

Sarconeos is currently in clinical development for treating adults aged 45 or over who are hospitalised with COVID-19. COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The main symptoms of COVID-19 are fever, a new continuous cough, and loss of taste or smell. In some patients, COVID-19 may result in severe complications, such as acute respiratory distress syndrome, blood clotting, acute heart or kidney injury, and sepsis. Hospitalisation and death rates amongst COVID-19 patients remains high. Patients with conditions that cause immune impairment, who are less likely to mount an adequate protective response after COVID-19 vaccination, are at high risk of developing severe COVID-19. There is a need to develop additional therapeutics to protect these vulnerable patients and reduce the risk of poor outcomes from exposure to COVID-19.